Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Final ICH Addendum Offers Latest Perspectives On Pediatric Drug Development

Executive Summary

A new document that complements the International Council for Harmonisation's existing guideline on pediatric clinical trials is expected to reduce the likelihood of significant differences among countries on the acceptance of data generated in pediatric global drug development programs

You may also be interested in...



ICH Expansion To Bring New Challenges For Global Consensus On Pediatric Extrapolation

The pharmaceutical industry is cautiously optimistic about the ambitious three-year timeline decided by the International Council for Harmonisation for its new guideline on pediatric extrapolation. However, ensuring consensus on this fast-developing concept will be a challenge as more regulators will have a seat at the discussion table as ICH expands.

Industry Sees Little Benefit Of New EU Clinical Trial Rules On Information Materials For Minors

The European pharmaceutical industry trade group, EFPIA, is concerned about new requirements proposed in a draft European Commission guideline about how sponsors should prepare and test information materials used for obtaining informed consent from minors participating in clinical trials. It has, however, welcomed proposed changes on the use of a “staggered approach” to recruiting minors into trials.

ICH Agrees On New Extrapolation Guideline To Support Pediatric Development

The International Council for Harmonisation took several key decisions at it latest meeting in Canada, such as developing a new dedicated guideline on extrapolation, admitting a group representing the world's leading pharmaceutical inspectorates as an observer, and adopting revised rules and procedures to ensure the ICH remains ‘agile’ as it grows.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS121543

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel